跳至主要内容
临床试验/NCT06067217
NCT06067217招募中不适用

Comparative Study of Tranexamic Acid, Estrogen for Treatment Abnormal Uterine Bleeding in Depot-medroxyprogesterone Acetate Users. A Randomized Controlled Trial

Rajavithi Hospital2 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2023年9月30日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
52
试验地点
2
主要终点
Day to stop abnormal uterine bleeding between groups after receiving Tranexamic acid and estrogen

研究概览

简要总结

Abnormal uterine bleeding is the most common problems to discontinue Depo-medroxyprogesterone acetate (DMPA) in Thailand. This clinical trial use to provide drug to stop abnormal uterine bleeding from DMPA

详细描述

Abnormal uterine bleeding is the most common problems to discontinue Depo-medroxyprogesterone acetate (DMPA) in Thailand. After discontinue DMPA, patients have not used any method. Unwanted pregnancy are rising. The reason of abnormal uterine bleeding from DMPA aren't clearly understand. In present, no standard treatment to treat abnormal utrerine bleeding in DMPA users.This clinical trial use to provide drug to stop abnormal uterine bleeding from DMPA with minimal dose and minimal side effect

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

盲法说明

Drug in concealed envelop which participant and care provider aren't see

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Abnormal uterine bleeding more than 7 days after first DMPA injection
  • Provide inform consent with patient
  • Can understand thai language

排除标准

  • Have contraindication to use Tranexamic acid and estrogen such as hypertension, Stroke, MI, DM, Renal disease, Liver disease, CA breast etc.
  • Have pathology in uterus from pelvic examination, pap smear and ultrasound
  • Current pelvic infection
  • Postpartum less than 6 months
  • History deep vein thrombosis
  • Breastfeeding

研究组 & 干预措施

Tranexamic acid

Experimental

Tranexamic acid 250 mg oral three times/day

干预措施: Tranexamic acid 250 mg oral tablet (Drug)

Progynova

Experimental

Progynova 1 mg oral three times/day

干预措施: Progynova 1 mg oral tablet (Drug)

结局指标

主要结局

Day to stop abnormal uterine bleeding between groups after receiving Tranexamic acid and estrogen

时间窗: 1 week after intervention

To Compare day to stop abnormal uterine bleeding between groups after receiving Tranexamic acid and estrogen

次要结局

  • Frequency of bleeding after DMPA injection(after DMPA injection)
  • Side effect after receiving Tranexamic acid(1 week after intervention)
  • Side effect after receiving estrogen(1 week after intervention)

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验